{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:21:30Z","timestamp":1790108490738,"version":"4.0.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","journals.elsevierhealth.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.eururo.2016.03.034","type":"journal-article","created":{"date-parts":[[2016,4,13]],"date-time":"2016-04-13T12:47:24Z","timestamp":1460551644000},"page":"341-347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Intravesical Bacillus Calmette-Gu\u00e9rin Versus Combination of Epirubicin and Interferon-\u03b12a in Reducing Recurrence of Non\u2013Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study"],"prefix":"10.1016","volume":"70","author":[{"given":"Timo","family":"Marttila","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riikka","family":"J\u00e4rvinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapani","family":"Liukkonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkki","family":"Rintala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bostr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjo","family":"Sepp\u00e4nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teuvo","family":"Tammela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pekka","family":"Hellstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirpa","family":"Aaltomaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markku","family":"Leskinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Raitanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eero","family":"Kaasinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2016.03.034_bib0115","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","article-title":"EAU guidelines on non\u2013muscle-invasive urothelial carcinoma of the bladder: update 2013","volume":"64","author":"Babjuk","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.03.034_bib0120","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Gu\u00e9rin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.03.034_bib0125","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.eururo.2013.05.027","article-title":"Maintenance bacillus Calmette-Gu\u00e9rin treatment of non\u2013muscle-invasive bladder cancer: a critical evaluation of the evidence","volume":"64","author":"Ehdaie","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.03.034_bib0130","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.eururo.2015.02.022","volume":"68","author":"J\u00e4rvinen","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.03.034_bib0135","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/1078-1439(95)00041-F","article-title":"Randomized intergroup comparison of bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder: a Southwest Oncology Group study","volume":"1","author":"Lamm","year":"1995","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2016.03.034_bib0140","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.eururo.2008.01.015","article-title":"The schedule and duration of intravesical chemotherapy in patients with non\u2013muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials","volume":"53","author":"Sylvester","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.03.034_bib0145","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1464-410X.2010.10040.x","article-title":"Co-administration of intravesical bacillus Calmette-Gu\u00e9rin and interferon \u03b1-2b as first line in treating superficial transitional cell carcinoma of the urinary bladder","volume":"108","author":"Bazarbashi","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2016.03.034_bib0150","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0022-5347(05)65757-6","article-title":"Salvage intravesical therapy with interferon \u03b1-2b plus low dose bacillus Calmette-Gu\u00e9rin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Gu\u00e9rin alone previously failed","volume":"166","author":"O\u2019Donnell","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.03.034_bib0155","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S0022-5347(17)39547-2","article-title":"A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder","volume":"144","author":"Glashan","year":"1990","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.03.034_bib0160","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00001813-199205000-00005","article-title":"A pilot study comparing different dose levels and administration schedules of interferon-alpha 2b combined with epirubicin for prevention of recurrence in bladder cancer","volume":"3","author":"Serretta","year":"1992","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.eururo.2016.03.034_bib0165","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00001813-199205000-00008","article-title":"Interferon-alpha 2b instillation prophylaxis in superficial bladder cancer\u2013a prospective, controlled three-armed trial. Project Group Bochum\u2013Interferon and Superficial Bladder Cancer","volume":"3","author":"Engelmann","year":"1992","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.eururo.2016.03.034_bib0170","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1464-410X.1995.tb00759.x","article-title":"A controlled study of intravesical epirubicin with or without alpha2b-interferon as prophylaxis for recurrent superficial transitional cell carcinoma","volume":"76","author":"Raitanen","year":"1995","journal-title":"Br J Urol"},{"key":"10.1016\/j.eururo.2016.03.034_bib0175","first-page":"479","article-title":"Clinical trial with intravesical alfa-2b interferon for the prevention of T1 transitional carcinoma of the bladder: preliminary results. Review of the bibliography","volume":"48","author":"Portillo Mart\u00edn","year":"1995","journal-title":"Arch Esp Urol"},{"key":"10.1016\/j.eururo.2016.03.034_bib0180","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.eururo.2009.09.038","article-title":"Bacillus Calmette-Gu\u00e9rin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study","volume":"57","author":"Duchek","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.03.034_bib0185","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.juro.2013.11.005","article-title":"5-year outcome of a randomized prospective study comparing bacillus Calmette-Gu\u00e9rin with epirubicin and interferon-\u03b12b in patients with T1 bladder cancer","volume":"191","author":"Hemdan","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.03.034_bib0190","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.03.034_bib0195","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.03.034_bib0200","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2014.09.026","volume":"67","author":"Solsona","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.03.034_bib0205","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1056\/NEJM199110243251703","article-title":"A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Gu\u00e9rin for transitional-cell carcinoma of the bladder","volume":"325","author":"Lamm","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2016.03.034_bib0210","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1200\/JCO.1987.5.3.441","article-title":"A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Gu\u00e9rin therapy of superficial bladder cancer","volume":"3","author":"Badalament","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2016.03.034_bib0215","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/1097-0142(19950115)75:2<552::AID-CNCR2820750219>3.0.CO;2-H","article-title":"Bacillus Calmette-Guerin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder","volume":"75","author":"Akaza","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2016.03.034_bib0220","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eururo.2009.04.009","volume":"56","author":"J\u00e4rvinen","year":"2009","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283816300100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283816300100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T15:03:29Z","timestamp":1567782209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283816300100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S0302283816300100"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2016.03.034","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravesical Bacillus Calmette-Gu\u00e9rin Versus Combination of Epirubicin and Interferon-\u03b12a in Reducing Recurrence of Non\u2013Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2016.03.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}